Trials / Active Not Recruiting
Active Not RecruitingNCT05479994
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Adult Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of BGB-11417 in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Conditions
- Leukemia
- Lymphoma
- Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Small Lymphocytic Lymphoma
- Relapsed Chronic Lymphocytic Leukemia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGB-11417 | Administered orally |
Timeline
- Start date
- 2022-10-25
- Primary completion
- 2025-01-24
- Completion
- 2027-08-25
- First posted
- 2022-07-29
- Last updated
- 2026-03-04
Locations
50 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05479994. Inclusion in this directory is not an endorsement.